JP2013539468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539468A5 JP2013539468A5 JP2013526189A JP2013526189A JP2013539468A5 JP 2013539468 A5 JP2013539468 A5 JP 2013539468A5 JP 2013526189 A JP2013526189 A JP 2013526189A JP 2013526189 A JP2013526189 A JP 2013526189A JP 2013539468 A5 JP2013539468 A5 JP 2013539468A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- seq
- notum
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims description 82
- 101150025249 Notum gene Proteins 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 238000007798 limiting dilution analysis Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000001613 neoplastic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000013115 immunohistochemical detection Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 3
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 3
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000018732 detection of tumor cell Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 238000011002 quantification Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000014306 paracrine signaling Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37788210P | 2010-08-27 | 2010-08-27 | |
| US61/377,882 | 2010-08-27 | ||
| US38018110P | 2010-09-03 | 2010-09-03 | |
| US61/380,181 | 2010-09-03 | ||
| US38855210P | 2010-09-30 | 2010-09-30 | |
| US61/388,552 | 2010-09-30 | ||
| US201161510413P | 2011-07-21 | 2011-07-21 | |
| US61/510,413 | 2011-07-21 | ||
| PCT/US2011/049458 WO2012027723A1 (en) | 2010-08-27 | 2011-08-26 | Notum protein modulators and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030708A Division JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013539468A JP2013539468A (ja) | 2013-10-24 |
| JP2013539468A5 true JP2013539468A5 (https=) | 2014-10-09 |
Family
ID=44741704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526189A Ceased JP2013539468A (ja) | 2010-08-27 | 2011-08-26 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
| JP2016030708A Pending JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030708A Pending JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130224191A1 (https=) |
| EP (1) | EP2608807A1 (https=) |
| JP (2) | JP2013539468A (https=) |
| KR (1) | KR20140018837A (https=) |
| CN (1) | CN103260646B (https=) |
| AU (2) | AU2011293127B2 (https=) |
| BR (1) | BR112013004776A2 (https=) |
| CA (1) | CA2809369A1 (https=) |
| CO (1) | CO6700829A2 (https=) |
| MX (1) | MX2013002255A (https=) |
| PE (1) | PE20140190A1 (https=) |
| PH (1) | PH12013500379A1 (https=) |
| RU (1) | RU2013113638A (https=) |
| SG (2) | SG10201506782XA (https=) |
| WO (1) | WO2012027723A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120266260A1 (en) * | 2009-05-26 | 2012-10-18 | Hitoshi Suzuki | Diagnosing and treating iga nephropathy |
| CA2809369A1 (en) * | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
| EP2611463A2 (en) * | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| JP6033229B2 (ja) * | 2010-11-24 | 2016-11-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体 |
| US8802365B2 (en) * | 2011-03-22 | 2014-08-12 | Whitehead Institute For Biomedical Research | Methods for identifying candidate modulators of NOTUM activity |
| EP2729496B8 (en) | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
| CN105143470B (zh) | 2013-02-28 | 2020-06-09 | 德克萨斯大学系统董事会 | 用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法 |
| WO2015054427A1 (en) | 2013-10-10 | 2015-04-16 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
| JP2017501211A (ja) | 2013-11-06 | 2017-01-12 | アスチュート メディカル，インコーポレイテッド | 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ |
| US20160356794A1 (en) * | 2014-02-10 | 2016-12-08 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
| KR20150105505A (ko) * | 2014-03-06 | 2015-09-17 | (주)노바셀테크놀로지 | 신규 대장암의 바이오마커 및 그를 표적으로 하는 항암제 |
| US20170158753A1 (en) * | 2014-06-25 | 2017-06-08 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| WO2017196819A2 (en) * | 2016-05-09 | 2017-11-16 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof |
| EP3585403A4 (en) | 2017-02-22 | 2020-12-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHEMERICAL ANTIGENIC RECEPTORS BINDING TO TIM3 |
| BR112019019595A2 (pt) * | 2017-03-23 | 2020-04-14 | Univ Pennsylvania | anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula |
| US11525004B2 (en) | 2017-07-20 | 2022-12-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant CD123-binding antibodies |
| AU2020298324A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
| CN110950960B (zh) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 |
| WO2021242757A1 (en) * | 2020-05-26 | 2021-12-02 | The Trustees Of The University Of Pennsylvania | Monocolonal antibodies against pathological tau, and methods using same |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN117430702B (zh) * | 2022-07-21 | 2024-06-21 | 东莞市朋志生物科技有限公司 | 抗b型尿钠肽抗体或其功能性片段、检测b型尿钠肽的试剂和试剂盒 |
| AU2024227909A1 (en) * | 2023-02-28 | 2025-08-14 | Mayo Foundation For Medical Education And Research | Molecules that bind to b-cell activating factor receptor polypeptides |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| JPH08501085A (ja) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗腫瘍剤としてのサイトカインｉｐ−１０の利用 |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| JPH10503371A (ja) | 1994-07-29 | 1998-03-31 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1997034911A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU753157B2 (en) | 1997-11-03 | 2002-10-10 | Georgetown University Medical Center | VEGI, an inhibitor of angiogenesis and tumor growth |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| ES2324280T3 (es) * | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| ES2334773T3 (es) | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| GB0201808D0 (en) * | 2002-01-25 | 2002-03-13 | European Molecular Biology Lab Embl | Protein |
| AU2003217930A1 (en) | 2002-03-04 | 2003-09-22 | Medimmune, Llc | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7371840B2 (en) * | 2003-01-08 | 2008-05-13 | The University Of Southern California | Isolation and characterization of ECA1, a gene overexpressed in endometrioid carcinomas of ovary and endometrium |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| DK1633784T3 (da) | 2003-05-09 | 2011-10-24 | Diadexus Inc | OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder |
| EP1652923B1 (en) * | 2003-08-08 | 2011-10-12 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
| US20070037204A1 (en) * | 2003-08-08 | 2007-02-15 | Hiroyuki ABURANTAI | Gene overexpressed in cancer |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| EP2032694A4 (en) | 2006-06-06 | 2010-09-15 | Univ Tennessee Res Foundation | COMPOSITIONS ENRICHED WITH NEOPLASTIC STEM CELLS AND THESE COMPREHENSIVE METHODS |
| ES2646545T3 (es) | 2006-09-07 | 2017-12-14 | Arthur E. Frankel | Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3 |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| CA2809369A1 (en) * | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
| JP6033229B2 (ja) * | 2010-11-24 | 2016-11-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体 |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-08-26 CA CA2809369A patent/CA2809369A1/en not_active Abandoned
- 2011-08-26 AU AU2011293127A patent/AU2011293127B2/en not_active Ceased
- 2011-08-26 BR BR112013004776A patent/BR112013004776A2/pt not_active Application Discontinuation
- 2011-08-26 JP JP2013526189A patent/JP2013539468A/ja not_active Ceased
- 2011-08-26 SG SG10201506782XA patent/SG10201506782XA/en unknown
- 2011-08-26 PH PH1/2013/500379A patent/PH12013500379A1/en unknown
- 2011-08-26 PE PE2013000347A patent/PE20140190A1/es not_active Application Discontinuation
- 2011-08-26 MX MX2013002255A patent/MX2013002255A/es unknown
- 2011-08-26 SG SG2013014261A patent/SG187965A1/en unknown
- 2011-08-26 EP EP11752429.8A patent/EP2608807A1/en not_active Withdrawn
- 2011-08-26 WO PCT/US2011/049458 patent/WO2012027723A1/en not_active Ceased
- 2011-08-26 CN CN201180052205.9A patent/CN103260646B/zh not_active Expired - Fee Related
- 2011-08-26 US US13/819,208 patent/US20130224191A1/en not_active Abandoned
- 2011-08-26 RU RU2013113638/10A patent/RU2013113638A/ru not_active Application Discontinuation
- 2011-08-26 KR KR1020137007609A patent/KR20140018837A/ko not_active Withdrawn
-
2013
- 2013-03-15 CO CO13052190A patent/CO6700829A2/es unknown
-
2015
- 2015-05-06 US US14/705,842 patent/US20150322166A1/en not_active Abandoned
-
2016
- 2016-02-22 JP JP2016030708A patent/JP2016119906A/ja active Pending
- 2016-04-14 AU AU2016202380A patent/AU2016202380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539468A5 (https=) | ||
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP7308191B2 (ja) | 抗ｃｄ４７剤ベースの卵巣癌療法 | |
| CN111699005A (zh) | 使用抗cd47抗体和抗cd20抗体的抗癌方案 | |
| US10611839B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
| JP2014193862A (ja) | 新規な抗ｉｇｆ−ｉｒ抗体及びその使用 | |
| WO2019222188A1 (en) | Methods of treating cancer | |
| AU2016213773A1 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF | |
| HUE030578T2 (en) | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation | |
| CN110072550A (zh) | 用于治疗脑癌的组合疗法 | |
| TR201903026T4 (en) | S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES. | |
| US11667700B2 (en) | Anti-PCNA monoclonal antibodies and use thereof | |
| Smith et al. | PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma | |
| JP2019517504A (ja) | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断 | |
| CN119656302A (zh) | 治疗主体中c1013g/cxcr4相关的华氏巨球蛋白血症的药物组合物、评估方法及药剂盒 | |
| JP7739269B2 (ja) | がん療法のための複合バイオマーカー | |
| JP2023113613A (ja) | チェックポイント阻害薬のための予測末梢血バイオマーカー | |
| WO2020040245A1 (ja) | 抗体薬物複合体の感受性マーカー | |
| JP2022519649A (ja) | がんの診断および治療方法 | |
| CN117321418A (zh) | 癌症生物标志物及其使用方法 | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| JP2025124676A (ja) | インテグリンα１０および侵攻性癌型 | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| EP4593961A1 (en) | Treatment of drug-resistant hepatocellular carcinoma |